Tags

Type your tag names separated by a space and hit enter

Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease.
J Alzheimers Dis 2005; 8(4):359-67JA

Abstract

Dementia from Alzheimer's disease (AD) represents a significant and growing public health burden and presents a clear therapeutic imperative. Key to success in this undertaking will be biomarkers for the objective assessment of disease progression and response to therapeutics. Oxidative damage is one facet of AD pathogenesis for which there are experimentally validated quantitative in vivo biomarkers, the F2-isoprostanes (IsoPs). While plasma- or urine-based assays are desirable, consistent and reproducible cross-sectional data for increased F2-IsoPs in AD and mild cognitive impairment have been obtained only for CSF. In addition, measurement of CSF F2-IsoPs can increase the accuracy of laboratory-based classification of geriatric dementias, and have been used to assess objectively the response to anti-oxidant interventions in AD.

Authors+Show Affiliations

Department of Pathology, University of Washington, Seattle, WA 98104, USA. tmontine@u.washington.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16556967

Citation

Montine, Thomas J., et al. "Quantitative in Vivo Biomarkers of Oxidative Damage and Their Application to the Diagnosis and Management of Alzheimer's Disease." Journal of Alzheimer's Disease : JAD, vol. 8, no. 4, 2005, pp. 359-67.
Montine TJ, Quinn JF, Montine KS, et al. Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. J Alzheimers Dis. 2005;8(4):359-67.
Montine, T. J., Quinn, J. F., Montine, K. S., Kaye, J. A., & Breitner, J. C. (2005). Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. Journal of Alzheimer's Disease : JAD, 8(4), pp. 359-67.
Montine TJ, et al. Quantitative in Vivo Biomarkers of Oxidative Damage and Their Application to the Diagnosis and Management of Alzheimer's Disease. J Alzheimers Dis. 2005;8(4):359-67. PubMed PMID: 16556967.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. AU - Montine,Thomas J, AU - Quinn,Joseph F, AU - Montine,Kathleen S, AU - Kaye,Jeffrey A, AU - Breitner,John C S, PY - 2006/3/25/pubmed PY - 2006/10/13/medline PY - 2006/3/25/entrez SP - 359 EP - 67 JF - Journal of Alzheimer's disease : JAD JO - J. Alzheimers Dis. VL - 8 IS - 4 N2 - Dementia from Alzheimer's disease (AD) represents a significant and growing public health burden and presents a clear therapeutic imperative. Key to success in this undertaking will be biomarkers for the objective assessment of disease progression and response to therapeutics. Oxidative damage is one facet of AD pathogenesis for which there are experimentally validated quantitative in vivo biomarkers, the F2-isoprostanes (IsoPs). While plasma- or urine-based assays are desirable, consistent and reproducible cross-sectional data for increased F2-IsoPs in AD and mild cognitive impairment have been obtained only for CSF. In addition, measurement of CSF F2-IsoPs can increase the accuracy of laboratory-based classification of geriatric dementias, and have been used to assess objectively the response to anti-oxidant interventions in AD. SN - 1387-2877 UR - https://www.unboundmedicine.com/medline/citation/16556967/Quantitative_in_vivo_biomarkers_of_oxidative_damage_and_their_application_to_the_diagnosis_and_management_of_Alzheimer's_disease_ L2 - https://content.iospress.com/openurl?genre=article&issn=1387-2877&volume=8&issue=4&spage=359 DB - PRIME DP - Unbound Medicine ER -